The current standard of care for identifying targetable mutations in cancer treatment is to conduct molecular profiles on tumor tissue samples, but a study published in JAMA Network Open indicates that adding liquid biopsy testing for circulating tumor DNA mutations increases targetable mutation detection rates.
From left to right: Geoffrey Shapiro, Leif Ellisen and Nancy Lin. Sitting below them is Kornelia Polyak.The Dana-Farber/Harvard Cancer Center, a cancer research consortium comprised of five of Boston’s academic medical centers, including Dana-Farber Cancer Institute and Massachusetts General Hospital, has been awarded an NCI grant to continue its Specialized Program of Research Excellence in Breast Cancer.
